for those that like press releases

Here is the website below:
I have included the article below it.
http://www.streetinsider.com/Press+Releases/The+Global+RNAi+Market+is+Projected+to+Grow+at+25.6%25+Compounded+Annually+From+2005+to+2012/3439211.html




The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually From 2005 to 2012
More News related to Press Releases
Comeback to a Pre-Injury Level After Elbow or Shoulder Surgery Disappointing for Pro Baseball Players
Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term
Study Reveals Emergency On-Field Treatment for Neck Injuries in Young Collision Sports Athletes No Different Than Adults
PepsiCo Donates $1 Million to UNCF
PepsiCo Donates $1 Million to UNCF
More News related to Press Releases
March 7, 2008 11:00 AM EST

DUBLIN, Ireland--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/reports/c85063) has announced the addition of RNAi 2008 to their offering.

This Market Insight Report on RNAi covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions-United States, Europe, Asia-Pacific and Rest of World. The RNAi Tools/Products are further segmented into Design/Software (miRNA Target Scan, miRNA Analysis Software, and Design Software), Synthesis (Expression Vectors, Chemical, iRNA Isolation, Dicer/RNAseIII, and In Vitro), Delivery (Vector Based, Transfection Reagents, and Electroporation), Monitoring/Optimizing (Primers for RTqPCR, Controls, and miRNA Detection Tools), and Libraries (Human, Mouse, and Rat). Application by Research (Functional Genomics, Metabolism, and Protein Chemistry), Therapeutics (Oncology, Neurology, Ophthalmology, and Virology) and Drug Development (Target Identification, Target Validation, and Drug Mechanism) are also analyzed. Business profiles of 42 major companies are discussed in the report. The report serves as a guide to global RNAi industry covering 213 companies that are engaged in RNAi synthesis, R&D, therapeutics, test kits, tools and services. Major Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Projections and estimates are graphically illustrated by geographic, region with exclusive graphical representations provided for 384 exhibits.

RNA interference, a term coined by Andy Fire and Craig Mello for their discovery which won them a Nobel Prize in 2006, is abbreviated as RNAi. It stands for the regulation mechanism of gene expression by RNA in living organisms. Andy Fire and Craig Mello worked on Ceonorhabditis elegans. RNAi is induced by miRNA/siRNA. These molecules, in association with RNA induced silencing complexes (RISC), bind to target mRNA and degrade it. There are other proteins involved in the accomplishment of this mechanism, which may differ in different organisms.

Prior to characterization, RNAi was known by other names such as gene silencing and post transcriptional transgene. It was only after the characterization at the molecular level it was recognized as the same phenomenon.

Global RNAi market is projected to grow at 25.6% compounded annually from 2005 to 2012. United States maintains its lead throughout. US and Europe are fore runners in RNAi based therapeutics. Asia-Pacific and Rest of World rank high in terms of CAGR.

Ambion, Dharmacon, Invitrogen and Qiagen continue to dominate the market for RNAi products. However their positions vary across market segments and geographic regions. Ambion, Invitrogen and Qiagen products are used equally in academia and industry, while Dharmacon is cited as a supplier far more frequently by industrial researchers than by academic researchers.

Numerous companies have sprung up capitalizing on the RNAi phenomenon. Pharma and biotech companies are looking at RNAi as a key drug discovery tool. RNAi compounds are expected to hit the market at least 5 years away. Clinical trials are underway and post efficacy in animals, huge investments are likely to trigger the RNAi market. Collaborations, mergers, alliances, and licenses are expected to occur in a huge manner. In the coming years, market shares of the companies in RNAi products will majorly be driven by innovations in delivery tools, monitoring and optimizing aids, as a survey reveals dissatisfaction in these areas largely, while improvisations in design/software, synthesis and library tools will be an added advantage and give a better edge.

Companies Mentioned:

Actigenics SA (France)

Allele Biotechnology and Pharmaceuticals, Inc. (USA)

alphaGEN Co., Ltd. (Japan)

Alnylam Pharmaceuticals, Inc. (USA)

Ambion, Inc. (USA)

Antisense Therapeutics Limited (Australia)

Applied Biosystems Group (USA)

Asuragen, Inc. (USA)

Avalon Pharmaceuticals, Inc. (USA)

Benitec Ltd. (Australia)

B-Bridge International, Inc (USA)

Clontech Laboratories, Inc. (USA)

Calando Pharmaceuticals, Inc. (USA)

Cenix Bioscience GmbH (Germany)

CombiMatrix Corporation (USA)

CytoPathfinder, Inc. (Japan)

CytRx Corporation (USA)

RXi Pharmaceuticals Corporation (USA)

deVGen NV (Belgium)

Dharmacon, Inc. (USA)

Galenea Corporation (USA)

Imgenex Corporation (USA)

Intradigm Corporation (USA)

Intronn, Inc. (USA)

Invitrogen Corporation (USA)

InvivoGen (USA)

Lentigen Corporation (USA)

Merck & Co., Inc. (USA)

Mirus Bio Corporation (USA)

Nastech Pharmaceutical Company, Inc. (USA)

Nucleonics, Inc. (USA)

Open Biosystems, Inc. (USA)

Opko Health, Inc. (USA)

Panomics, Inc. (USA)

Promega Corporation (USA)

Qiagen N.V. (The Netherlands)

RNAx GmbH (Germany)

SomaGenics, Inc. (USA)

Santaris Pharma A/S (Denmark)

Sigma-Aldrich Corporation (USA)

Silence Therapeutics plc (UK)

Targeted Genetics Corporation (USA)